



**CANADIAN CANCER TRIALS GROUP
2016 Spring Meeting of Participants**

**INVESTIGATIONAL NEW DRUG (IND) COMMITTEE OPEN SESSION
Friday, April 29, 2016
9:00 AM – 12:00 PM**

AGENDA

Chairs: Dr. Scott Laurie and Dr. Philippe Bedard
IND Program Director: Dr. Lesley Seymour

Time	Topic	Presenter
9:00 – 9:05	Welcome	Scott Laurie
9:05 – 9:15	Dr. Elizabeth Eisenhauer Early Drug Development Young Investigator Awardee presentation I	Marshall Pitz
9:15 – 9:25	Dr. Elizabeth Eisenhauer Early Drug Development Young Investigator Awardee presentation II	Rachel Goodwin
9:25 – 9:45	Changing clinical trials landscape in Europe and Italy	Francesco Perrone
9:45 – 10:05	Turning a cold immunologic tumor hot: how to put fire in the belly of the beast	James Gulley
10:05 – 10:25	Targeting HR deficient cancers with G-quadruplex stabilizing compounds	Sam Aparicio
10:25 – 10:35	Coffee break	
10:35 – 10:50	A Phase Ib Study Of Durvalumab (Medi4736) With Or Without Tremelimumab In Patients With Advanced Incurable Solid Malignancies Receiving Standard Chemotherapy Regimens – IND.226	Rosalyn Juergens Desiree Hao
10:50 – 11:05	A Randomized Phase II Study Of Reolysin In Combination With FOLFOX6/Bevacizumab Or FOLFOX6/Bevacizumab Alone In Patients With Metastatic Colorectal Cancer – IND.210	Derek Jonker
11:05 – 11:20	A Randomized Phase II Study Of Reolysin In Patients With Previously Treated Advanced Or Metastatic, Non-Small Cell Lung Cancer Receiving Standard Salvage Therapy – IND.211	Don Morris
11:20 – 11:35	New IND trials	Lesley Seymour Greg Korpanty
11:35 – 11:55	Discussion	
11:55 – 12:00	Closing remarks	Philippe Bedard

IND OPEN COMMITTEE MEETING OBJECTIVES

- To summarize aspects of recent developments in the understanding of immunotherapy, novel therapeutic agents as these relate to specific malignancies and their therapeutic targets.
- To discuss changes in the clinical trials' landscape in the European Union based on Italian experience.
- To describe and discuss results of recent Investigational New Drug studies conducted by the CCTG.
- To understand aspects new clinical trial methodologies in the field of early cancer drug development.